Recruitment

Recruitment Status
Completed

Inclusion Criteria

body mass index between 18 and 27 kg/m2
Written informed consent
Healthy male subjects; 18 - 40 years of age
...
body mass index between 18 and 27 kg/m2
Written informed consent
Healthy male subjects; 18 - 40 years of age
Non-smoking behaviour
Normal findings in medical & bleeding history

Exclusion Criteria

Impaired renal function (serum creatinine > 1.3 mg/dl)
Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease)
Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration
...
Impaired renal function (serum creatinine > 1.3 mg/dl)
Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease)
Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration
Regular daily consumption of more than on litre of xanthine-containing beverages or more than 40g alcohol
Participation in another clinical trial during the preceding 3 weeks
Impaired liver function (AST, ALT, GGT >2 x ULN, Bilirubin >1.5 x ULN)
Any other relevant deviation from the normal range in clinical chemistry, haematology or urine analysis
HIV-1/2-Ab, HbsAg or HCV-Ab positive serology
Known allergy against test agents
Known disorders with increased bleeding risk (e.g. peridontitis, haemorrhoids, acute gastritis, peptic ulcer, intestinal ulcer)
History of thromboembolism
Known sensitivity to common causes of bleeding (e.g. nasal)
Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg
Anaemia (defined as haemoglobin levels < LLN)

Summary

Conditions
  • Acute Coronary Syndrome
  • Atrial Fibrillation
Type
Interventional
Phase
Phase 1
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 40 years
Gender
Only males

Inclusion Criteria

body mass index between 18 and 27 kg/m2
Written informed consent
Healthy male subjects; 18 - 40 years of age
...
body mass index between 18 and 27 kg/m2
Written informed consent
Healthy male subjects; 18 - 40 years of age
Non-smoking behaviour
Normal findings in medical & bleeding history

Exclusion Criteria

Impaired renal function (serum creatinine > 1.3 mg/dl)
Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease)
Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration
...
Impaired renal function (serum creatinine > 1.3 mg/dl)
Known coagulation disorders (e.g. haemophilia, von Willebrand´s disease)
Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration
Regular daily consumption of more than on litre of xanthine-containing beverages or more than 40g alcohol
Participation in another clinical trial during the preceding 3 weeks
Impaired liver function (AST, ALT, GGT >2 x ULN, Bilirubin >1.5 x ULN)
Any other relevant deviation from the normal range in clinical chemistry, haematology or urine analysis
HIV-1/2-Ab, HbsAg or HCV-Ab positive serology
Known allergy against test agents
Known disorders with increased bleeding risk (e.g. peridontitis, haemorrhoids, acute gastritis, peptic ulcer, intestinal ulcer)
History of thromboembolism
Known sensitivity to common causes of bleeding (e.g. nasal)
Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg
Anaemia (defined as haemoglobin levels < LLN)

Tracking Information

NCT #
NCT02080858
Collaborators
Not Provided
Investigators
Not Provided
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024